PHILADELPHIA –- John Gearhart, who led a research team that first identified and isolated human embryonic stem cells, has been named director of the Institute for Regenerative Medicine at the University of Pennsylvania and also a Penn Integrates Knowledge Professor.

John Gearhart

John Gearhart (Image Credit: Johns Hopkins University)

Click on thumbnail
to view full-size image

Gearhart is the James W. Effron University Professor at Penn. His appointment is jointly shared between the Department of Cell and Developmental Biology in the School of Medicine and the Department of Animal Biology in the School of Veterinary Medicine.

"John Gearhart combines cutting-edge research, education and public service in regenerative medicine," Penn President Amy Gutmann said. "His decision to join the Penn faculty will lead our stem cell research program to global preeminence, and bolster Penn's already strong commitment to translational bench-to-bedside research.

"America's continued vitality, growth and health," she said, "depend directly on our nation's commitment to scientists and scientific research. We expect that Dr. Gearhart and his colleagues will help to galvanize public support for indisputably crucial stem cell research initiatives."

Gearhart has been a leading advocate for the federal funding of stem cell research. His groundbreaking work focuses on the role of genes in regulating the formation of human tissues and embryos, especially as it relates to mental
retardation, Down syndrome and other congenital birth defects.

"John Gearhart's arrival reaffirms Penn's place at the forefront of medical and scientific research," Penn Provost Ron Daniels said. "He is the ideal director for our new Institute for Regenerative Medicine, as he has been a leader in both research breakthroughs and public discussion."

Gearhart also becomes the eighth Penn Integrates Knowledge Professor. The PIK program was launched by Gutmann in 2005 as a University-wide initiative to recruit exceptional faculty members whose research and teaching exemplify the integration of knowledge across disciplines and who are jointly appointed between two schools at Penn.

Gearhart was previously the C. Michael Armstrong Professor of Medicine and the director of stem cell biology and the Division of Developmental Genetics at the Johns Hopkins University School of Medicine. He received his Ph.D. in genetics in 1970 from Cornell University, M.Sc. in plant genetics in 1966 from the University of New Hampshire and B.Sc. in biology in 1964 from Penn State University.

The James W. Effron University Professorship is the gift of Craig W. Effron, a 1981 Penn graduate. The professorship is named in honor of his father, James W. Effron.

Craig Effron, a founding partner of Scoggin Capital Management, a hedge fund in New York, is a member of the University Committee on Undergraduate Financial Aid, co-chair of the Major Gift Committee of Penn's Making History fund-raising campaign and a strong advocate for making Penn more financially accessible.

To offer incentives for scholarship gifts, he created the Craig Effron Challenge Fund to provide matching dollars for new scholarship funds.

###

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Share This Page: